Viz.ai vs Abridge

By valuation, Abridge is the larger company at $5.3B versus $1.2B — a 4.4x difference. Size can also be measured by team: Viz.ai employs 275 people while Abridge has 120 employees.

Abridge has raised more in total funding at $800M, compared to Viz.ai's $289M — a gap of $511M. Combined, the two companies have completed 8 known funding rounds.

Abridge leads with an Awaira Score of 76/100, while Viz.ai sits at 66/100. That 10-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Viz.ai was founded by Chris Mansi in 2016. Abridge was founded by Shiv Rao in 2018. Visit each company's profile on Awaira for a full founder biography.

Viz.ai: Viz.ai is an artificial intelligence healthcare company founded in 2016 that develops clinical decision support software for medical imaging analysis. The company specializes in AI-powered diagnostic tools that assist radiologists and emergency physicians in identifying acute neurological and cardiovascular conditions from medical imaging scans. Viz.ai's core platform uses deep learning algorithms to detect conditions such as stroke, pulmonary embolism, and aortic dissection, prioritizing urgent cases and flagging them for immediate physician review. The company's primary products include stroke detection software and platforms for identifying other time-critical conditions in emergency departments. Viz.ai operates within the broader clinical AI segment, competing with companies developing similar diagnostic imaging solutions. The platform integrates into existing hospital workflows and imaging infrastructure, providing real-time alerts to clinicians. Viz.ai has achieved significant market validation, with its technology adopted across numerous healthcare systems in the United States. The company raised Series D funding at a $1.2 billion valuation, reflecting investor confidence in the clinical AI market. Total funding reached $289 million across multiple rounds. The company's growth trajectory demonstrates expanded adoption among major hospital networks and healthcare providers seeking to improve diagnostic speed and clinical outcomes for emergency conditions. Viz.ai focuses specifically on time-critical emergency conditions where AI-assisted early detection directly impacts patient outcomes and hospital operations. Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology uses natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence.

Viz.ai got there first, launching in 2016 — that's 2 years of extra runway. Abridge didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Viz.ai has about 275 employees; Abridge has about 120. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Viz.ai and Abridge compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.